The Effect of PROCRIT (Epoetin Alfa) on Postoperative Vigor and Handgrip Strength (VIGOR Study)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00401869
Recruitment Status : Completed
First Posted : November 22, 2006
Last Update Posted : April 6, 2010
Information provided by:
Ortho Biotech Clinical Affairs, L.L.C.

Brief Summary:
The purpose of this study was to compare the effect of epoetin alfa to preoperative autologous blood donation (PAD) on postoperative vigor (a measure of functional ability and well-being) and handgrip strength in patients undergoing hip or knee surgery.

Condition or disease Intervention/treatment Phase
Anemia Drug: Epoetin alfa Phase 4

Detailed Description:
Total joint arthroplasty (including hip and knee surgery) often leads to significant blood loss and may result in the need for blood transfusion. To prepare for this possibility, patients frequently donate their own blood in advance of their surgery so that it is available if transfusion is required during or after the procedure. This process of self-donation is known as preoperative autologous blood donation (PAD). PAD is associated with certain limitations including for example, worsening pre-operative anemia (potentially leading to the need for transfusion) and questionable cost-effectiveness. PROCRIT (Epoetin alfa) is a hormone that stimulates red blood cells production. Administration of PROCRIT (Epoetin alfa) is also used presurgically in anemic patients undergoing elective noncardiac, nonvascular surgery to increase hemoglobin levels (red blood cells) and reduce the need for transfusion during or after surgery. PROCRIT (Epoetin alfa) has been shown specifically to increase hemoglobin levels and reduce the need for blood transfusion in patients who undergo hip or knee surgery. However, no studies have been done to evaluate the ability of epoetin alfa to enhance energy and quality-of-life in patients having hip or knee surgery. This study was undertaken to compare two methods of blood management (Epoetin alfa treatment versus PAD) in terms of vigor score (functional activity and well-being). Other outcomes of study include handgrip strength, post-operative hemoglobin levels, and number of patients requiring transfusion. This was a randomized (patients were assigned to each treatment group by chance), open-label (both patient and physician know what treatment group the patient is assigned to) trial. Patients randomly assigned to treatment with PROCRIT (Epoetin alfa) received a subcutaneous injection of 600 IU/kg once weekly for 3 weeks preoperatively and then within 24 hours postoperatively. Patients in the PAD group were to donate 1 unit of blood before total knee arthroplasty, and 2 units of blood before total hip arthroplasty, as tolerated, beginning up to 28 days before surgery. Patients were not permitted to receive both study treatments. Daily oral iron supplementation was given in both treatment groups. It was recommended that blood transfusions should not be given if the patient had hemoglobin greater than or equal to 8 g/dL unless clinical symptoms or patient history warranted intervention. Investigators were instructed to use identical criteria for autologous and allogeneic blood transfusions. Baseline measurements including hemoglobin, hematocrit, red blood cell count, white blood cell count, reticulocytes, vigor, and handgrip strength were collected 28 to 21 days before surgery. Hemoglobin, vigor, and handgrip strength were repeated within 24 hours before surgery and again on Day 2, Day 4 or 5 (or discharge), and once between days 14 to 21 after surgery. Safety was assessed throughout the study by monitoring the occurrence and severity of adverse events including infection and thromboembolism. Patients assigned to the epoetin alfa group received 600 IU/kg PROCRIT (Epoetin alfa) administered subcutaneously (under the skin) once weekly for 3 weeks preoperatively and once 24 hours after surgery.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 289 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: The Effect of PROCRIT on Hemoglobin and Hematocrit and the Relationship to Postoperative Function, Vigor and Strength in Patients Undergoing Primary Total Joint Arthroplasty: A Randomized, Parallel Group, Open-Label Trial
Study Start Date : February 1999
Actual Study Completion Date : December 2001

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Primary Outcome Measures :
  1. The change in VIGOR score (as assessed by questionnaire) from baseline to 1) within 24 hours of surgery; 2) post-op Day 2; 3) Day 4 or 5 or hospital discharge; and 4) between post-op days 14 and 21.

Secondary Outcome Measures :
  1. Handgrip strength (JAMAR Hand Dynamometer using the stronger hand and in a standardized position and method repeated 3 times - the maximum force exerted was recorded), hemoglobin, and incidence of transfusion as described for primary outcome intervals.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Scheduled for elective unilateral (one joint), primary total joint arthroplasty of hip or knee
  • pretreatment hemoglobin level of 11 to 14 g/dL
  • enrollment 21-60 days in advance of surgery

Exclusion Criteria:

  • No uncontrolled hypertension
  • No seizure disorder
  • No history of deep vein thrombosis
  • No significant gastrointestinal bleeding in previous 6 months
  • No clinically significant hematologic, cardiovascular, neurological, pulmonary, endocrine, gastrointestinal, or genitourinary disease

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00401869

Sponsors and Collaborators
Ortho Biotech, Inc.
Study Director: Ortho Biotech, Inc. Clinical Trial Ortho Biotech, Inc.

Publications of Results: Identifier: NCT00401869     History of Changes
Obsolete Identifiers: NCT00526825
Other Study ID Numbers: CR012205
First Posted: November 22, 2006    Key Record Dates
Last Update Posted: April 6, 2010
Last Verified: April 2010

Keywords provided by Ortho Biotech Clinical Affairs, L.L.C.:

Additional relevant MeSH terms:
Epoetin Alfa